{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:38Z","timestamp":1790776598967,"version":"4.1.0"},"reference-count":125,"publisher":"Informa UK Limited","issue":"15","funder":[{"name":"Cardiff University and the Life Science Research Network Wales","award":["NUC-1031 and NUC-3373"],"award-info":[{"award-number":["NUC-1031 and NUC-3373"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.4155\/fmc-2017-0095","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T15:42:25Z","timestamp":1505922145000},"page":"1809-1833","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":79,"title":["Fluorinated Nucleosides as an Important Class of Anticancer and Antiviral Agents"],"prefix":"10.1080","volume":"9","author":[{"given":"Alessandra","family":"Cavaliere","sequence":"first","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NBWales, UK"},{"name":"Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XNWales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin C","family":"Probst","sequence":"additional","affiliation":[{"name":"Wales Research & Diagnostic Positron Emission Tomography Imaging Centre (PETIC), School of Medicine, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XNWales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Westwell","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NBWales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Slusarczyk","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NBWales, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.4155\/9781909453968"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfluchem.2006.01.011"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.443"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1139(02)00201-4"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm981097r"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00258"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.200800222"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201204687"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666140202205035"},{"key":"e_1_3_2_12_1","first-page":"1","article-title":"A tabulated summary of the FDG PET literature","volume":"42","author":"Gambhir SS","year":"2001","unstructured":"Gambhir SS , CzerninJ, SchwimmerJet al. A tabulated summary of the FDG PET literature. J. Nucl. Med.42, 1\u201394 (2001).","journal-title":"J. Nucl. Med."},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3197"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr010374q"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/cc020087f"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr800464r"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2010.04.010"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo100504x"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1039\/c2cc16158c"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.organomet.6b00059"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1021\/op049884n"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2010.01.003"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2012.06.008"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.6b00209"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2015.01.001"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.6b01845"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.05.015"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejoc.201402755"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557043403936"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/cr5002035"},{"issue":"15","key":"e_1_3_2_31_1","first-page":"15.5.1","article-title":"Synthesis of phosphoramidate prodrugs: ProTide approach","volume":"53","author":"Serpi M","year":"2013","unstructured":"Serpi M , MadelaK, PertusatiFet al. Synthesis of phosphoramidate prodrugs: ProTide approach. Curr. Protoc. Nucleic Acid Chem.53 (15.5), 15.5.1\u201315.5.15 (2013).","journal-title":"Curr. Protoc. Nucleic Acid Chem."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401853a"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.64.070195.003445"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci400131y"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568011023354146"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-4-325"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp300370t"},{"key":"e_1_3_2_38_1","unstructured":"ClinicalTrials.gov . www.clinicaltrials.gov."},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200815w"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.05.024"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.TARG-15-B46"},{"issue":"14","key":"e_1_3_2_42_1","article-title":"First-in-human Phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanisms","volume":"76","author":"Blagden SP","year":"2016","unstructured":"Blagden SP , SlusarczykM, SerpiMet al. First-in-human Phase I study of the nucleotide analogue NUC-3373 designed to overcome fluoropyrimidine drug resistance mechanisms. Cancer Res.76 (14 Suppl.), Abstract CT028 (2016).","journal-title":"Cancer Res."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.1.7"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.11.1395"},{"issue":"6","key":"e_1_3_2_45_1","first-page":"371","article-title":"Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity","volume":"1","author":"Kroep JR","year":"2002","unstructured":"Kroep JR , LovesWJP, van der WiltCLet al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther.1 (6), 371\u2013376 (2002).","journal-title":"Mol. Cancer Ther."},{"issue":"14","key":"e_1_3_2_46_1","first-page":"4024","article-title":"Comparison of the cellular pharmacokinetics and toxicity of 2\u2032,2\u2032-difluorodeoxycytidine and 1-\u03b2-D-arabinofuranosylcytosine","volume":"48","author":"Heinemann V","year":"1988","unstructured":"Heinemann V , HertelLW, GrindeyGBet al. Comparison of the cellular pharmacokinetics and toxicity of 2\u2032,2\u2032-difluorodeoxycytidine and 1-\u03b2-D-arabinofuranosylcytosine. Cancer Res.48 (14), 4024\u20134031 (1988).","journal-title":"Cancer Res."},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4885"},{"issue":"3","key":"e_1_3_2_48_1","first-page":"533","article-title":"Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate: a mechanism of self-potentiation","volume":"52","author":"Heinemann V","year":"1992","unstructured":"Heinemann V , XuYZ, ChubbSet al. Cellular elimination of 2\u2032,2\u2032-difluorodeoxycytidine 5\u2032-triphosphate: a mechanism of self-potentiation. Cancer Res.52 (3), 533\u2013539 (1992).","journal-title":"Cancer Res."},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm901181h"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0353"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0207-9"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-009-9377-7"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-011-9756-8"},{"key":"e_1_3_2_54_1","volume-title":"33rd European Society for Medical Oncology (ESMO) Congress","author":"Aamdal S","year":"2008","unstructured":"Aamdal S . First-in-man study of a novel nucleoside analogue, CP-4126, in patients with advanced solid tumours. 33rd European Society for Medical Oncology (ESMO) Congress. Stockholm, Sweden, 12\u201316 September 2008 (Poster 496P)."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.0826"},{"key":"e_1_3_2_56_1","unstructured":"Another pancreatic cancer drug hits the dust - Clavis\/Clovis\u2019 CP-4126. www.thepharmaletter.com\/article\/another-pancreatic-cancer-drug-hits-the-dust-clavis-clovis-cp-4126."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0224"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2655"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602673"},{"issue":"4","key":"e_1_3_2_60_1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0026-895X(24)12530-8","article-title":"Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine","volume":"56","author":"Saboulard D","year":"1999","unstructured":"Saboulard D , NaesensL, CahardDet al. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. Mol. Pharmacol.56 (4), 693\u2013704 (1999).","journal-title":"Mol. Pharmacol."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-CT401"},{"key":"e_1_3_2_62_1","article-title":"Final results from the first in-human Phase I\/II study of NUC-1031 in patients with solid tumours. 2015 ASCO Annual Meeting","volume":"33","author":"Blagden SP","year":"2015","unstructured":"Blagden SP , SuppiahP, O'SheaDet al. Final results from the first in-human Phase I\/II study of NUC-1031 in patients with solid tumours. 2015 ASCO Annual Meeting. J. Clin. Oncol.33 (Suppl.), Abstract 2514 (2015).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00254a018"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2011.244"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2015.2974"},{"issue":"2","key":"e_1_3_2_66_1","first-page":"247","article-title":"The clinical pharmacology of 5-trifluoromethyl-2\u2032-deoxyuridine","volume":"32","author":"Dexter DL","year":"1972","unstructured":"Dexter DL , WolbergWH, AnsfieldFJet al. The clinical pharmacology of 5-trifluoromethyl-2\u2032-deoxyuridine. Cancer Res.32 (2), 247\u2013253 (1972).","journal-title":"Cancer Res."},{"issue":"2","key":"e_1_3_2_67_1","first-page":"449","article-title":"Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo","volume":"27","author":"Emura T","year":"2005","unstructured":"Emura T , SuzukiN, FujiokaAet al. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int. J. Oncol.27 (2), 449\u2013455 (2005).","journal-title":"Int. J. Oncol."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00477.x"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/1074-5521(95)90084-5"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2006.09.009"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm3004009"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-013-0025-x"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162901"},{"key":"e_1_3_2_74_1","unstructured":"Adis Insight: Fluorocyclopentenylcytosine . http:\/\/adisinsight.springer.com\/drugs\/800022534."},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s3688"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53162-8"},{"issue":"2","key":"e_1_3_2_78_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0026-895X(25)10347-7","article-title":"Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs","volume":"31","author":"Parker WB","year":"1987","unstructured":"Parker WB , ChengYC. Inhibition of DNA primase by nucleoside triphosphates and their arabinofuranosyl analogs. Mol. Pharmacol.31 (2), 146\u2013151 (1987).","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"e_1_3_2_79_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0026-895X(25)09779-2","article-title":"Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase","volume":"34","author":"Parker WB","year":"1988","unstructured":"Parker WB , BapatAR, ShenJXet al. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol.34 (4), 485\u2013491 (1988).","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"e_1_3_2_80_1","first-page":"2349","article-title":"Comparison of the toxicity and metabolism of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine and 9-\u03b2-D-arabinofuranosyladenine in human lymphoblastoid cells","volume":"40","author":"Plunkett W","year":"1980","unstructured":"Plunkett W , ChubbS, AlexanderLet al. Comparison of the toxicity and metabolism of 9-\u03b2-D-arabinofuranosyl-2-fluoroadenine and 9-\u03b2-D-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res.40 (7), 2349\u20132355 (1980).","journal-title":"Cancer Res."},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(87)90207-3"},{"issue":"10","key":"e_1_3_2_82_1","first-page":"1225","article-title":"Central nervous system toxicity of fludarabine phosphate","volume":"70","author":"Chun HG","year":"1986","unstructured":"Chun HG , Leyland-JonesBR, CarykSMet al. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep.70 (10), 1225\u20131228 (1986).","journal-title":"Cancer Treat. Rep."},{"issue":"5","key":"e_1_3_2_83_1","first-page":"33","article-title":"Phase I clinical trials with fludarabine phosphate","volume":"17","author":"Von Hoff DD","year":"1990","unstructured":"Von Hoff DD . Phase I clinical trials with fludarabine phosphate. Semin. Oncol.17 (5 Suppl. 8), 33\u201338 (1990).","journal-title":"Semin. Oncol."},{"issue":"9","key":"e_1_3_2_84_1","first-page":"4183","article-title":"Phase I clinical investigation of 9-\u03b2 -D-arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate (NSC 312887), a new purine antimetabolite","volume":"44","author":"Hutton JJ","year":"1984","unstructured":"Hutton JJ , Von HoffDD, KuhnJet al. Phase I clinical investigation of 9-\u03b2 -D-arabinofuranosyl-2-fluoroadenine 5\u2032-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res.44 (9), 4183\u20134186 (1984).","journal-title":"Cancer Res."},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-172254"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-115"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.06.094"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2055"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.015768"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.53.2.270"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.7.2970"},{"issue":"9","key":"e_1_3_2_92_1","first-page":"2386","article-title":"Effects of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2 -D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032-triphosphate","volume":"51","author":"Parker WB","year":"1991","unstructured":"Parker WB , ShaddixSC, ChangCHet al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2 -D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5\u2032-triphosphate. Cancer Res.51 (9), 2386\u20132394 (1991).","journal-title":"Cancer Res."},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.03.010"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1919"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-016-0254-0"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4010"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3002(59)90597-9"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6215(00)00089-6"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00187a005"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2009.45.5.1377596"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfluchem.2008.06.007"},{"issue":"4","key":"e_1_3_2_102_1","first-page":"e6056","article-title":"Virological response and muscular adverse events during long-term Clevudine therapy in chronic hepatitis B patients","volume":"13","author":"Kim BK","year":"2013","unstructured":"Kim BK , KoSY, KwonSYet al. Virological response and muscular adverse events during long-term Clevudine therapy in chronic hepatitis B patients. Hepat. Mon.13 (4), e6056 (2013).","journal-title":"Hepat. Mon."},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510263331702"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00170a015"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2088"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26275"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1086\/656774"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(01)90749-5"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo00246a002"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632029000100211"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00444.x"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.03.092"},{"key":"e_1_3_2_113_1","unstructured":"Kates DE . Application for inclusion of Emtricitabine on WHO model list of essential medicines. Gilead Sciences Inc. CA USA (2006). http:\/\/archives.who.int\/eml\/expcom\/expcom15\/applications\/newmed\/emtri\/Emtricitabine.pdf."},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565100-00008"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020501600204"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2010.509345"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666150625094705"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01156-16"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02250-13"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967"},{"key":"e_1_3_2_121_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100863x"},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113209990178"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.142464"},{"issue":"5","key":"e_1_3_2_124_1","first-page":"345","article-title":"Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection","volume":"39","author":"Cha A","year":"2014","unstructured":"Cha A , BudovichA. Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection. P&T39 (5), 345\u2013352 (2014).","journal-title":"P&T"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.11.023"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05639-11"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2015.07.002"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc-2017-0095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T20:53:28Z","timestamp":1750884808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc-2017-0095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":125,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.4155\/fmc-2017-0095"],"URL":"https:\/\/doi.org\/10.4155\/fmc-2017-0095","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-06-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}